TX45疗法的TX45药物显示,在第一阶段b试验中,在改善心脏功能方面很有希望。 Tectonic Therapeutic's TX45 drug shows promise in improving heart function in a Phase 1b trial.

德克通疗法公司报告了TX45的成功1b期试验结果,显示它能很好地耐受并改善2组肺高血压患者的心力衰竭与保存的射出分数相关的心脏功能. Tectonic Therapeutic has reported successful Phase 1b trial results for TX45, showing it is well-tolerated and improves heart function in patients with Group 2 pulmonary hypertension related to heart failure with preserved ejection fraction. 药物的好处持续了29天 The drug's benefits lasted for 29 days. 德克通公司希望在欧洲心脏病学会心力衰竭2025活动上展示这些发现,并计划进行更多的试验. Tectonic expects to present these findings at the European Society of Cardiology Heart Failure 2025 event and plans more trials.